Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration-Reference-Cited by-同舟云学术

Cefiderocol Pharmacokinetics in a Patient Receiving Continuous Venovenous Hemodiafiltration

Published:2021-05-25 Issue:7 Volume:8 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Kobic Emir¹,Gill Christian M²,Mochon A Brian³⁴,Nicolasora Nelson P⁵,Nicolau David P²⁶

Affiliation:

1. Department of Pharmacy, Banner University Medical Center, Phoenix, Arizona, USA

2. Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA

3. Department of Pathology, University of Arizona College of Medicine, Phoenix, Arizona, USA

4. Labratory Sciences Arizona/Sonora Quest Laboratories, Phoenix, Arizona, USA

5. Division of Infectious Diseases, Banner University Medical Center, Phoenix, Arizona, USA

6. Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA

Abstract

Abstract Antimicrobial dosing in patients receiving continuous renal replacement therapy is a continued clinical challenge. We describe a case of a patient receiving cefiderocol 2 g intravenously every 8 hours as a 3-hour infusion for a multidrug-resistant Pseudomonas aeruginosa pneumonia and bacteremia while undergoing continuous venovenous hemodiafiltration. The clinical course and cefiderocol pharmacokinetics are described.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab252/38197681/ofab252.pdf

Reference16 articles.

1. In vitro antimicrobial activity of S-649266, a catechol-substituted siderophore cephalosporin, when tested against non-fermenting gram-negative bacteria;Ito;J Antimicrob Chemother,2016

2. Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for gram-negative bacteria, in healthy subjects;Saisho;Antimicrob Agents Chemother,2018

3. Cefiderocol, a siderophore cephalosporin for gram-negative bacterial infections: pharmacokinetics and safety in subjects with renal impairment;Katsube;J Clin Pharmacol,2017

4. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections;Shields;Clin Infect Dis,2016

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A New Dosing Frontier: Retrospective Assessment of Effluent Flow Rates and Residual Renal Function Among Critically Ill Patients Receiving Continuous Renal Replacement Therapy;Critical Care Explorations;2024-03-22

2. Continuous infusion of cefiderocol in a critically ill patient with continuous venovenous haemofiltration;British Journal of Clinical Pharmacology;2023-09-20

3. Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF);International Journal of Antimicrobial Agents;2023-08

4. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence;Annals of Intensive Care;2023-06-15

5. Jumping into the future: overcoming pharmacokinetic/pharmacodynamic hurdles to optimize the treatment of severe difficult to treat-Gram-negative infections with novel beta-lactams;Expert Review of Anti-infective Therapy;2023-01-31